MNLO News and Press, VYNE Therapeutics

BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Confe...

Menlo Therapeutics ( MNLO )  changed its name to Vyne Therapeutics and will trade under the symbol to 'VYNE'; effective trading today. More news on: Menlo Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

BRIDGEWATER, N.J. , Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "...

Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”...

Menlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Matthew Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Conferenc...

Menlo Therapeutics (NASDAQ: MNLO ) : Q2 GAAP EPS of -$1.21 misses by $0.93 . Revenue of $11.7M beats by $9.66M . Shares -1.9% PM. Press Release More news on: Menlo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news,

BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today...

BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today...

Our analysis concludes Menlo Therapeutics ( MNLO ) is materially undervalued primarily because, at $1.70 per share, MNLO's enterprise valuation is slightly less than $200MM which is less than 80% of its estimated peak annual sales. In early March 2020 (just before most of the country went into...

Since January of this year, shares of Menlo Therapeutics ( MNLO ) (formerly Foamix) have been cut by roughly two-thirds, given the fallout of the Coronavirus pandemic, as well as the lackluster result of the merger between Foamix and Menlo to form the newly combined company. With the failure o...